These underappreciated dividend payers offer yields above 4% at recent prices.The past year has been terrific for most stocks. The S&P 500 index rose 27.5% during the 12 months ended Aug. 26.It's always nice to see the value of your portfolio rise during a bull market, but it also makes it hard to find stocks to buy at reasonable valuations.Investors seeking reliable dividend stocks that still look like bargains will be glad to know that not all of the S&P 500's components have had a great year. Pfizer (PFE ...

Bristol Myers (BMY) announced that the FDA has accepted its supplemental Biologics License Application (sBLA) for the immunotherapy drug, Opdivo (nivolumab), in combination with Yervoy (ipilimumab).The sBLA seeks approval of Opdivo plus Yervoy as a potential first-line treatment option for adult patients with unresectable hepatocellular carcinoma (HCC). A final decision from the regulatory body in the United States is expected on Apr 21, 2025.Bristol Myers’ application is based on results from the late-stag ...

Bristol Myers Squibb (BMY) announced that the European Medicines Agency (“EMA”) has validated its type II variation application to expand the indication for CD19-directed chimeric antigen receptor (CAR) T cell therapy Breyanzi (lisocabtagene maraleucel; liso-cel).The application seeks to expand Breyanzi’s label to include the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) who have received two or more prior lines of systemic therapy.Validation of the application confirms th ...

With yields above 4%, these stocks could do a lot to boost your passive income streamThe S&P 500 index is up by about 16% so far this year. Many of the index's dividend payers have raised their payouts, but not nearly as much as their stock prices have risen. As a result, the average dividend-paying stock in the benchmark index offers a paltry 1.3% yield at recent prices.Luckily, there are still a handful of top dividend payers trading for low enough prices to offer high yields. Here's why they could be gre ...

The drugmaker will go through key changes by the end of the decade.Bristol Myers Squibb (BMY 0.51%) has had a rough past five years. Its shares are barely in the green, its financial results have been unimpressive, and it has faced important patent cliffs. Most notably, its cancer drug Revlimid, its top-selling product at one point, is now out of patent exclusivity.Despite that poor showing in recent years, things might be very different for BMS in the next half-decade, but only if it can better handle the ...

Investors might want to bet on Bristol Myers Squibb (BMY) , as it has been recently upgraded to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one of the most powerful forces impacting stock prices -- has triggered this rating change.A company's changing earnings picture is at the core of the Zacks rating. The system tracks the Zacks Consensus Estimate -- the consensus measure of EPS estimates from the sell-side analysts covering the stock -- for the current and following years.The power of ...

Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either Bristol Myers Squibb (BMY) or Vertex Pharmaceuticals (VRTX) . But which of these two stocks is more attractive to value investors? We'll need to take a closer look to find out.We have found that the best way to discover great value opportunities is to pair a strong Zacks Rank with a great grade in the Value category of our Style Scores system. The proven Zacks Rank emphasizes companies with positive es ...

Bristol Myers Squibb (BMY) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.Over the past month, shares of this biopharmaceutical company have returned +12.2%, compared to the Zacks S&P 500 composite's -2.9% change. During this period, the Zacks Medical - Biomedical and Genetics industry, which Bristol Myers falls in, has lost 0.1%. The key question now is: What could be the stoc ...

WATERTOWN, Mass., Aug. 15, 2024 (GLOBE NEWSWIRE) -- Abata Therapeutics, a company focused on transforming lives with Treg therapies for severe autoimmune and inflammatory diseases, today announced it has received an equity investment from Bristol Myers Squibb to support the development of its Treg cell therapy products. Their investment supports Abata's continued advancement into the clinic, with trial initiation imminent for ABA-101 in progressive multiple sclerosis. “Given their leadership in cell therapy ...

Bristol Myers Squibb Company (BMY) has regained some of the lost territories in the past month, giving anxious investors a ray of hope. This biotech giant has been facing a few challenges for quite some time now.Shares of BMY have risen 16.4% in a month against the industry’s decline of 0.7%. The stock has also outperformed the sector and the S&P 500 in this period.The rally came after the company reported better-than-expected second-quarter results in July. Upside in blood-thinner drug Eliquis and immuno-o ...